Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

The Pharmacokinetics of 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy.

Bosgra S, Sipkens J, de Kimpe S, den Besten C, Datson N, van Deutekom J.

Nucleic Acid Ther. 2019 Aug 20. doi: 10.1089/nat.2019.0805. [Epub ahead of print]

PMID:
31429628
2.

Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy.

McDonald CM, Wong B, Flanigan KM, Wilson R, de Kimpe S, Lourbakos A, Lin Z, Campion G; DEMAND V study group.

Ann Clin Transl Neurol. 2018 Jul 11;5(8):913-926. doi: 10.1002/acn3.579. eCollection 2018 Aug.

3.

Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne.

Lourbakos A, Yau N, de Bruijn P, Hiller M, Kozaczynska K, Jean-Baptiste R, Reza M, Wolterbeek R, Koeks Z, Ayoglu B, de Klerk D, Campion G, Zaharieva I, Nadarajah VD, Nilsson P, Al-Khalili Szigyarto C, Muntoni F, Lochmüller H, Verschuuren JJ, Goemans N, Tulinius M, Niks EH, de Kimpe S, Aartsma-Rus A, 't Hoen PAC, Spitali P.

Sci Rep. 2017 Dec 20;7(1):17888. doi: 10.1038/s41598-017-17982-y.

4.

Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.

Goemans NM, Tulinius M, van den Hauwe M, Kroksmark AK, Buyse G, Wilson RJ, van Deutekom JC, de Kimpe SJ, Lourbakos A, Campion G.

PLoS One. 2016 Sep 2;11(9):e0161955. doi: 10.1371/journal.pone.0161955. eCollection 2016.

5.

Preclinical studies on intestinal administration of antisense oligonucleotides as a model for oral delivery for treatment of duchenne muscular dystrophy.

van Putten M, Young C, van den Berg S, Pronk A, Hulsker M, Karnaoukh TG, Vermue R, van Dijk KW, de Kimpe S, Aartsma-Rus A.

Mol Ther Nucleic Acids. 2014 Nov 18;3:e211. doi: 10.1038/mtna.2014.62.

6.

A sensitive, reproducible and objective immunofluorescence analysis method of dystrophin in individual fibers in samples from patients with duchenne muscular dystrophy.

Beekman C, Sipkens JA, Testerink J, Giannakopoulos S, Kreuger D, van Deutekom JC, Campion GV, de Kimpe SJ, Lourbakos A.

PLoS One. 2014 Sep 22;9(9):e107494. doi: 10.1371/journal.pone.0107494. eCollection 2014.

7.

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.

Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, De Kimpe SJ, Eagle M, Guglieri M, Hood S, Liefaard L, Lourbakos A, Morgan A, Nakielny J, Quarcoo N, Ricotti V, Rolfe K, Servais L, Wardell C, Wilson R, Wright P, Kraus JE.

Lancet Neurol. 2014 Oct;13(10):987-96. doi: 10.1016/S1474-4422(14)70195-4. Epub 2014 Sep 7.

PMID:
25209738
8.

The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice.

Verhaart IE, van Vliet-van den Dool L, Sipkens JA, de Kimpe SJ, Kolfschoten IG, van Deutekom JC, Liefaard L, Ridings JE, Hood SR, Aartsma-Rus A.

Mol Ther Nucleic Acids. 2014 Feb 18;3:e148. doi: 10.1038/mtna.2014.1.

9.

Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide.

Frazier KS, Sobry C, Derr V, Adams MJ, Besten CD, De Kimpe S, Francis I, Gales TL, Haworth R, Maguire SR, Mirabile RC, Mullins D, Palate B, Doorten YP, Ridings JE, Scicchitano MS, Silvano J, Woodfine J.

Toxicol Pathol. 2014 Jul;42(5):923-35. doi: 10.1177/0192623313505781. Epub 2013 Nov 28.

PMID:
24292388
10.

Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice.

Verhaart IE, Tanganyika-de Winter CL, Karnaoukh TG, Kolfschoten IG, de Kimpe SJ, van Deutekom JC, Aartsma-Rus A.

Nucleic Acid Ther. 2013 Jun;23(3):228-37. doi: 10.1089/nat.2012.0398. Epub 2013 May 2.

PMID:
23634945
11.

Long-term Exon Skipping Studies With 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models.

Tanganyika-de Winter CL, Heemskerk H, Karnaoukh TG, van Putten M, de Kimpe SJ, van Deutekom J, Aartsma-Rus A.

Mol Ther Nucleic Acids. 2012 Sep 4;1:e44. doi: 10.1038/mtna.2012.38.

12.

Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP).

Yılmaz-Eliş AS, Aartsma-Rus A, 't Hoen PA, Safdar H, Breukel C, van Vlijmen BJ, van Deutekom J, de Kimpe S, van Ommen GJ, Verbeek JS.

Mol Ther Nucleic Acids. 2013 Jan 22;2:e66. doi: 10.1038/mtna.2012.58.

13.

Antisense oligonucleotide mediated exon skipping as a potential strategy for the treatment of a variety of inflammatory diseases such as rheumatoid arthritis.

Yilmaz-Elis S, Aartsma-Rus A, Vroon A, van Deutekom J, de Kimpe S, 't Hoen PA, van Ommen GJ, Verbeek JS.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i75-7. doi: 10.1136/annrheumdis-2011-200971. No abstract available.

PMID:
22460143
14.

Systemic administration of PRO051 in Duchenne's muscular dystrophy.

Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, Sitsen JM, Aartsma-Rus A, van Ommen GJ, Buyse G, Darin N, Verschuuren JJ, Campion GV, de Kimpe SJ, van Deutekom JC.

N Engl J Med. 2011 Apr 21;364(16):1513-22. doi: 10.1056/NEJMoa1011367. Epub 2011 Mar 23. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.

15.

Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model.

Heemskerk H, de Winter C, van Kuik P, Heuvelmans N, Sabatelli P, Rimessi P, Braghetta P, van Ommen GJ, de Kimpe S, Ferlini A, Aartsma-Rus A, van Deutekom JC.

Mol Ther. 2010 Jun;18(6):1210-7. doi: 10.1038/mt.2010.72. Epub 2010 Apr 20.

16.

Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.

Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ, Furling D, Platenburg GJ, Gourdon G, Thornton CA, Wieringa B, Wansink DG.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13915-20. doi: 10.1073/pnas.0905780106. Epub 2009 Aug 10.

17.

In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.

Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.

J Gene Med. 2009 Mar;11(3):257-66. doi: 10.1002/jgm.1288.

PMID:
19140108
18.

Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.

Aartsma-Rus A, van Vliet L, Hirschi M, Janson AA, Heemskerk H, de Winter CL, de Kimpe S, van Deutekom JC, 't Hoen PA, van Ommen GJ.

Mol Ther. 2009 Mar;17(3):548-53. doi: 10.1038/mt.2008.205. Epub 2008 Sep 23.

19.

Local dystrophin restoration with antisense oligonucleotide PRO051.

van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ, Verschuuren JJ, van Ommen GJ.

N Engl J Med. 2007 Dec 27;357(26):2677-86.

20.

Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages.

Karimi K, Sarir H, Mortaz E, Smit JJ, Hosseini H, De Kimpe SJ, Nijkamp FP, Folkerts G.

Respir Res. 2006 Apr 19;7:66.

21.

FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection.

Ioan-Facsinay A, de Kimpe SJ, Hellwig SM, van Lent PL, Hofhuis FM, van Ojik HH, Sedlik C, da Silveira SA, Gerber J, de Jong YF, Roozendaal R, Aarden LA, van den Berg WB, Saito T, Mosser D, Amigorena S, Izui S, van Ommen GJ, van Vugt M, van de Winkel JG, Verbeek JS.

Immunity. 2002 Mar;16(3):391-402.

22.

Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats.

Attia DM, Verhagen AM, Stroes ES, van Faassen EE, Gröne HJ, De Kimpe SJ, Koomans HA, Braam B, Joles JA.

J Am Soc Nephrol. 2001 Dec;12(12):2585-93.

23.

Albumin restores lysophosphatidylcholine-induced inhibition of vasodilation in rat aorta.

Vuong TD, de Kimpe S, de Roos R, Rabelink TJ, Koomans HA, Joles JA.

Kidney Int. 2001 Sep;60(3):1088-96. Erratum in: Kidney Int 2001 Nov;60(5):2057.

24.

Opposite role of interferon-gamma and interleukin-4 on the regulation of blood pressure in mice.

van Heuven-Nolsen D, De Kimpe SJ, Muis T, van Ark I, Savelkoul H, Beems RB, van Oosterhout AJ, Nijkamp FP.

Biochem Biophys Res Commun. 1999 Jan 27;254(3):816-20.

PMID:
9920823
26.
27.

Role of nitric oxide in the circulatory failure and organ injury in a rodent model of gram-positive shock.

Kengatharan KM, De Kimpe SJ, Thiemermann C.

Br J Pharmacol. 1996 Dec;119(7):1411-21.

28.
29.
30.

The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure.

De Kimpe SJ, Kengatharan M, Thiemermann C, Vane JR.

Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10359-63.

31.
32.

Reversal of bradykinin-induced relaxation to contraction after interferon-gamma in bovine isolated mesenteric arteries.

De Kimpe SJ, Tielemans W, Van Heuven-Nolsen D, Nijkamp FP.

Eur J Pharmacol. 1994 Aug 11;261(1-2):111-20.

PMID:
8001633
33.

Induction of nitric oxide release by interferon-gamma inhibits vasodilation and cyclic GMP increase in bovine isolated mesenteric arteries.

De Kimpe SJ, Van Heuven-Nolsen D, van Amsterdam JG, Radomski MW, Nijkamp FP.

J Pharmacol Exp Ther. 1994 Feb;268(2):910-5.

PMID:
7509393
34.
35.

Bovine polymorphonuclear leukocytes increase sensitivity to noradrenaline in isolated mesenteric arteries.

De Kimpe SJ, Van Heuven-Nolsen D, Nijkamp FP.

Br J Pharmacol. 1992 Mar;105(3):581-6.

Supplemental Content

Loading ...
Support Center